A Phase II Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer.

Trial Profile

A Phase II Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2011

At a glance

  • Drugs Bafetinib (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms PROACT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Dec 2011 Additional lead trial investigator (Daniel Levitt) identified as reported by ClinicalTrials.gov.
    • 14 Dec 2011 Actual patient number (23) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top